Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin with bendamustine plus rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma
NL-OMON47634Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of polatuzumab vedotin, rituximab, obinutuzumab and bendamustine in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Roche. Primary endpoints: Complete response at primary response assessment by PET/CT, Objective response at primary response assessment by PET/CT and 5 more. Started Jun 2016; status: active, not recruiting.
02
Drugs
polatuzumab vedotinrituximabobinutuzumabbendamustine
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON47634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47634.